{"name":"Paul Beringer","slug":"paul-beringer","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPTXNXSFV5ajZVQWtpWTIwWERFUnBUaERTcUlDX0l3czRmTG85UGVadkpQZHhrcnJPdTNTbVloU3pUTWxwSGdmOXY2ZU9nQ2IybnpWaWctdHQtWk42dXNGdkxYQWZraTVWVEVncW1kQ1VRZjN1dlY4Q3dhcUwyazZJdWJuVl9RQkN5SFVWUWFPZUZyQQ?oc=5","date":"2025-07-17","type":"regulatory","source":"statnews.com","summary":"FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback - statnews.com","headline":"FDA advisers say risks of GSK blood cancer drug outweigh benefits in surprise setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1rVDRMRzF6Mndfb0dhVUFlMW1Ib1Nud0p6RTBrVmNsNFd4UjRpaTVtcWZRNmJ3eUpBdVI4Xzc4UnlTcDdSQl92Y1RmajdubldKZ3YxbWFDWlRRRmprcFNZdXl4RGNjdWVsRjBzUkc1Wl9yTm1MNzMyQUhFZw?oc=5","date":"2023-09-17","type":"regulatory","source":"medRxiv","summary":"Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor from the FDA Adverse Event Reporting System (FAERS) - medRxiv","headline":"Drug-induced liver injury associated with elexacaftor/tezacaftor/ivacaftor from the FDA Adverse Event Reporting System (","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPbi1mbjdCMVdHaGRRMHFNZzByTTZ6cC01TE5vRFdZSzJjbFdhQnV6eGd5empYZ1FqbGQ2X3BnTXM3SGpacnhncllsd01ybEpfcEhXR1RSM1dhVWpxdkRmS0p0MVpBUndLRDJsNm9nZFVWMkpneXd5VDJxdjZXZld5Rm5fMEFJTUxzeEJRcEhPTjVjMGVWNmJSeEwwRQ?oc=5","date":"2018-03-09","type":"pipeline","source":"keck.usc.edu","summary":"Beringer named chair of Titus Family Department of Clinical Pharmacy - keck.usc.edu","headline":"Beringer named chair of Titus Family Department of Clinical Pharmacy","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}